EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Improved Quality of Life and Sleep in Psoriasis Patients Treated With Guselkumab: The CASSIOPEE Study

L. Misery, Cristina Bulai Livideanu, A. C. Fougerousse, D. Staumont-Sallé, J. Baraut, S. Chaalal, R. Parker, M. A. Richard

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/9751619 ↗
AbstractBibliografische Angaben

Abstract

Background Psoriasis has physical, psychological, and social consequences that extend beyond visible lesions. Quality of life (QoL) is frequently affected by fatigue, sleep disturbance, and impaired intimacy or social functioning. Although biologics can achieve durable skin clearance, their broader effects on daily well‐being in routine practice are less well documented. The CASSIOPEE study assessed these multidimensional outcomes in patients treated with guselkumab. Objectives To evaluate the impact of guselkumab on QoL and objectively measured sleep in adults with moderate‐to‐severe psoriasis treated in routine clinical practice. Methods CASSIOPEE was a prospective, noninterventional, multicentre French study. Adults with moderate‐to‐severe psoriasis initiating guselkumab were followed for 6 months. The primary endpoint was Dermatology Life Quality Index (DLQI) response at month 6 (M6). Secondary outcomes included patient‐reported measures of general health (EQ‐5D‐5L), fatigue (FACIT‐Fatigue), anhedonia (SHAPS), sexual QoL (RSS), cognitive function (PDQ‐5), alexithymia (TAS‐20), and monthly electronic ratings of pain and pruritus. Sleep and physical activity were continuously monitored using a wearable device. Results Among the 207 enrolled patients, 88.9% achieved the DLQI minimal clinically important difference (MCID) by M6 and 60.1% had a DLQI score of 0/1. Sleep duration and quality improved, with 74.5% of patients gaining > 15 min/night and the proportion with high sleep quality increasing from 4.2% to 23.8%. Patient‐reported outcomes showed marked reductions in pruritus, skin pain, and fatigue, together with improvements in general health, sexual QoL, cognitive function, and anhedonia. Clinical effectiveness was reflected by 88.1% of patients achieving a Physician’s Global Assessment (PGA) score ≤ 1 and 55.1% reaching complete skin clearance at M6. Guselkumab was well tolerated; most adverse events were mild and 1.8% led to treatment discontinuation. Conclusions In routine practice, guselkumab was associated with broad benefits across skin and QoL domains, including a marked improvement in wearable‐confirmed sleep outcomes that paraleled symptom relief.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →